Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHART: Rezvilutamide vs Bicalutamide in Hormone Sensitive Prostate Cancer
NCT03520478Phase 3Unknown
- Sponsor
- Hengrui
- Start
- May 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Hengrui. Primary endpoints: Radiological Progression-Free Survival and Overall Survival. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03520478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520478.